Crossject Société Anonyme (74C.F)
| Previous close | 1.9760 |
| Open | 1.9760 |
| Bid | 1.9900 x 50000 |
| Ask | 2.0850 x 50000 |
| Day's range | 1.9760 - 1.9760 |
| 52-week range | 1.7420 - 5.7600 |
| Volume | |
| Avg. volume | 65 |
| Market cap | 71.381M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCrossject reports audited financial results for 2023
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company’s website. Key financial information as of December 31, 2023 Crossject’s financial results for the year ending December 31, 2023 have
- GlobeNewswire
Crossject trading on Euronext to resume as usual on Wednesday April 3
Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in such cases,
- GlobeNewswire
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025Reinforcement of supply chain [with addition of a second fill-and-finish CDMO]Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022 Dijon, France April 2, 2024, 10:30am CET -- Crossject (I
